After conducting over 10,000 automated internal network penetration tests last year, vPenTest has uncovered a troubling reality that many businesses still have critical security gaps that attackers ...
Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies – for $1.5 billion in cash. Cambridge, Massachusetts-based Orbital is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback